The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization

By Hokland S. L.   Horsman M. R.  

International Journal of Hyperthermia, Vol. 23, Iss. 7, 2007-01 ,pp. : 599-606

Informa Healthcare

Access to resources Recommend Favorite

Activity of the Vascular Targeting Agent Combretastatin A-4 Disodium Phosphate in a Xenograft Model of AIDS-Associated Kaposi's Sarcoma

By Rojiani Amyn M.   Li Lingyun   Rise Leroy   Siemann Dietmar W.  

Acta Oncologica, Vol. 41, Iss. 1, 2002-02 ,pp. : 98-105

Informa Healthcare

Access to resources Recommend Favorite

The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: A comparative assessment using MRI and MRS

By Breidahl Tomas   Nielsen Flemming   Stødkilde-Jørgensen Hans   Maxwell Ross   Horsman Michael  

Acta Oncologica, Vol. 45, Iss. 3, 2006-04 ,pp. : 306-316

Informa Healthcare

Access to resources Recommend Favorite

Preclinical Evaluations of Therapies Combining the Vascular Targeting Agent Combretastatin A-4 Disodium Phosphate and Conventional Anticancer Therapies in the Treatment of Kaposi's Sarcoma

By Li Lingyun   Rojiani Amyn M.   Siemann Dietmar W.  

Acta Oncologica, Vol. 41, Iss. 1, 2002-02 ,pp. : 91-97

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial

By Jameson M.   Baguley B.   Kestell P.   Zhao L.   Paxton J.   Thompson P.   Waller S.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 681-687

Springer Publishing Company

Access to resources Recommend Favorite